We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




COVID-19 Lung Damage Caused by Persistence of Abnormal Cells

By LabMedica International staff writers
Posted on 19 Nov 2020
Print article
Image: Histological features of COVID-19 lungs (Photo courtesy of the University of Trieste).
Image: Histological features of COVID-19 lungs (Photo courtesy of the University of Trieste).
Several uncertainties still relate to the involvement of other organs in COVID-19. Besides indirect multi-organ injury, a few reports have suggested the possibility of direct injury caused by viral replication in brain, heart and kidney.

Over the last couple of months a few studies have explored the lung pathology caused by COVID-19 infection in a small number of patients. The pattern that has emerged is that COVID-19 lung disease causes diffuse alveolar damage (DAD) which is also present in other conditions of acute respiratory distress syndrome (ARDS), including SARS.

A team of Medical Scientists at the University of Trieste (Trieste, Italy) analyzed the organs of 41 patients who died of COVID-19 at the University Hospital of Trieste. The team took lung, heart, liver, and kidney samples to examine the behavior of the virus. Of the 41 patients, six required intensive care, while 35 were hospitalized in either other hospital units or local nurseries until death. The average age of patients was 77 and 84 years for males and females, respectively. Hypertension, chronic cardiac disease, dementia, diabetes and cancer were the most common comorbidities. All patients eventually died of clinical acute respiratory distress syndrome.

At pathological examination, the investigators found that all cases exhibited lung damage and the lungs appeared congested at macroscopic examination. Meanwhile, histological analysis of all cases revealed gross destruction of the normal lung architecture, consistent with a condition of diffuse alveolar damage with edema, intra-alveolar fibrin deposition with hyaline membranes and hemorrhage. This was accompanied by occlusion of alveolar spaces due to cell delamination. Loss of cellular integrity was also confirmed by the presence of karyorrhexis, indicative of ongoing cellular death.

Further, in situ RNA hybridization for the detection of the SARS-CoV-2 genome indicated that the alterations in the lung were concomitant with persistent viral infection of pneumocytes and endothelial cells. RNA-positive pneumocytes were found to be largely present in the lungs of 10 of 11 tested individuals. The team said presence of abundant cytoplasmic RNA signals and expression of the Spike protein in the lungs after 30-40 days from diagnosis in the study suggests ongoing replication and postulates a continuous pathogenetic role of viral infection.

The scientists also noted that also noted the presence of anomalous epithelial cells among the cases which were characterized by abnormally large cytoplasm and, very commonly, by the presence of bi- of multi-nucleation. Presence of these dysmorphic cells was detected in 87% of patients. They added that the dysmorphic cells very often showed features of syncytia, characterized by several nuclei with an ample cytoplasm surrounded by a single plasma membrane. Most of these syncytia-forming, dysmorphic cells were bona fide pneumocytes.

The authors concluded that COVID-19 is a unique disease characterized by extensive lung thrombosis, long-term persistence of viral RNA in pneumocytes and endothelial cells, along with the presence of infected cell syncytia. Several of COVID-19 features might be consequent to the persistence of virus-infected cells for the duration of the disease. The study was published on November 3, 2020 in the journal EBioMedicine.

Related Links:
University of Trieste

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.